Rocket Pharmaceuticals Statistics
Share Statistics
Rocket Pharmaceuticals has 106.34M shares outstanding. The number of shares has increased by 17.49% in one year.
| Shares Outstanding | 106.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 16.88% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 96.86M |
| Failed to Deliver (FTD) Shares | 255.85K |
| FTD / Avg. Volume | 21.32% |
Short Selling Information
The latest short interest is 11.18M, so 10.51% of the outstanding shares have been sold short.
| Short Interest | 11.18M |
| Short % of Shares Out | 10.51% |
| Short % of Float | 11.54% |
| Short Ratio (days to cover) | 8.86 |
Valuation Ratios
The PE ratio is -10.25 and the forward PE ratio is -6.12.
| PE Ratio | -10.25 |
| Forward PE | -6.12 |
| PS Ratio | 0 |
| Forward PS | 5 |
| PB Ratio | 5.11 |
| P/FCF Ratio | -11.91 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.8, with a Debt / Equity ratio of 0.05.
| Current Ratio | 7.8 |
| Quick Ratio | 7.8 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.84 |
| Cash Flow / Debt | -7.78 |
| Interest Coverage | -138.48 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -50.16%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.43% |
| Return on Capital (ROIC) | -50.16% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -916.40K |
| Employee Count | 268 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.36% in the last 52 weeks. The beta is 1.09, so Rocket Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -63.36% |
| 50-Day Moving Average | 13.58 |
| 200-Day Moving Average | 19.21 |
| Relative Strength Index (RSI) | 28.97 |
| Average Volume (20 Days) | 1.20M |
Income Statement
| Revenue | n/a |
| Gross Profit | -7.10M |
| Operating Income | -259.66M |
| Net Income | -245.59M |
| EBITDA | -236.62M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.92 |
Balance Sheet
The company has 55.90M in cash and 25.04M in debt, giving a net cash position of 30.86M.
| Cash & Cash Equivalents | 55.90M |
| Total Debt | 25.04M |
| Net Cash | 30.86M |
| Retained Earnings | -959.37M |
| Total Assets | 393.69M |
| Working Capital | 201.77M |
Cash Flow
In the last 12 months, operating cash flow was -194.92M and capital expenditures -16.47M, giving a free cash flow of -211.39M.
| Operating Cash Flow | -194.92M |
| Capital Expenditures | -16.47M |
| Free Cash Flow | -211.39M |
| FCF Per Share | -2.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -27.94% |
| FCF Yield | -19.03% |
Analyst Forecast
The average price target for RCKT is $51, which is 388% higher than the current price. The consensus rating is "Buy".
| Price Target | $51 |
| Price Target Difference | 388% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Jan 5, 2018. It was a backward split with a ratio of 1:4.
| Last Split Date | Jan 5, 2018 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 6.7 |
| Piotroski F-Score | 3 |